Preparation of erlotinid hydrochloride
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- FUJIAN SOUTH PHARMA CO LTD
- Publication Date
- 2011-06-22
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
Technical field:
[0001] The invention relates to the field of synthesis of pharmaceutical compounds, in particular to a preparation method of 4-(3-ethynylphenylamino)-6,7-dimethoxyquinazoline hydrochloride (erlotinib hydrochloride). Background technique:
[0002] 4-(3-ethynylphenylamino)-6,7-dimethoxyquinazoline hydrochloride (erlotinib hydrochloride, Erlotinib Hydrochloride, trade name: Tarceva, Tarceva) is an epidermal growth factor (EGFR) Selective inhibitors of tyrosine kinases are currently clinically used for the treatment of non-small cell lung cancer.
[0003]
[0004] Erlotinib hydrochloride molecular structure
[0005] The synthetic route of erlotinib hydrochloride is mainly Schnur of U.S. Pfizer Inc.N.Y., Rodney.C. etc. report (US5747498), and its synthetic route is as follows:
[0006]
[0007] This route uses ethyl 3,4-dihydroxybenzoate as a raw material, first reacts with bromoethyl methyl ether, then nitrates, reduces nitro to amino, cyclizes, chlorate...